Russ Conroy

Data from a real-world study may help clinicians in treatment decision-making for those with extensive-stage small cell lung cancer who are unable to afford PD-L1 inhibitors.

The FDA sets a Prescription Drug User Fee Act date of June 12, 2024, for tarlatamab as a therapy for patients with advanced small cell lung cancer.

The Lurie Cancer Center Hispanic Breast Cancer Clinic taps into the efforts of Spanish-speaking physicians, social workers, and others to help treat Hispanic patients with breast cancer, says Claudia Tellez, MD.

Data from the phase 3 APPLY-PNH trial show comprehensive control of intravascular and extravascular hemolysis with iptacopan in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia.

Treatment with venetoclax appears to be well-tolerated in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, says Nilanjan Ghosh, MD, PhD.

Treatment with visugromab plus nivolumab in patients with relapsed/refractory solid tumors in the phase 2a GDFATHER-2 trial appears to exhibit safety and tolerability.

The safety profile of nivolumab plus ipilimumab in the phase 3 CheckMate 8HW trial is comparable with prior reports of each individual agent.

Treatment with iparomlimab appears to be tolerable in patients with unresectable or metastatic mismatch repair deficient or microsatellite instability–high solid tumors in a phase 2 trial.

Combining ribociclib with endocrine therapy appears to be effective and tolerable for those with hormone receptor–positive HER2-negative advanced breast cancer, including elderly patients.

Median overall survival appears to be higher in patients who were previously treated with relapsed/refractory mantle cell lymphoma and who receive brexucabtagene autoleucel compared with standard therapy.

The FDA has set a Prescription Drug User Fee Act date of April 5, 2024 for nivolumab plus chemotherapy in unresectable or metastatic urothelial carcinoma.

Implementing exercise programs into standard oncology care may help improve quality of life for patients with ovarian cancer.

Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial.

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials.

Investigators note a trend towards improved overall survival with cadonilimab plus chemotherapy with or without bevacizumab among those with cervical cancer in the phase 3 AK104-303 trial.

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.

Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.

Data from the phase 1/2 EPCORE NHL-1 trial support the FDA breakthrough therapy designation for epcoritamab-bysp in patients with previously treated relapsed/refractory follicular lymphoma.

Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.

Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

Data from the phase 2 FELIX study support the biologics license application for obecabtagene autoleucel as a treatment for patients with relapsed/refractory acute lymphoblastic leukemia.

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.

An artificial intelligence-based algorithm may help with tailoring treatment for patients with retroperitoneal sarcoma by clarifying the risks of their diseases, says Amani Arthur, MRCPCH.

The safety profile of durvalumab plus chemoradiation among patients with unresectable non–small cell lung cancer in the phase 3 PACIFIC-2 trial appears to be consistent with prior reports.

A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.

Companion diagnostic designation for FoundationOne CDx may improve access to treatment with capivasertib plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer harboring select alterations.

Findings from the phase 3 SKYSCRAPER-02 trial support outcomes following atezolizumab plus chemotherapy for patients with extensive-stage small cell lung cancer.